Insulet Corporation  

(Public, NASDAQ:PODD)   Watch this stock  
Find more results for podd
31.17
-0.14 (-0.45%)
Real-time:   11:37AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.98 - 31.84
52 week 27.02 - 51.31
Open 31.58
Vol / Avg. 258,328.00/919,476.00
Mkt cap 1.75B
P/E     -
Div/yield     -
EPS -0.88
Shares 56.08M
Beta 0.79
Inst. own 115%
Feb 25, 2015
Q4 2014 Insulet Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 14, 2015
Insulet Corp at JPMorgan Healthcare Conference
Dec 10, 2014
Insulet Corp at Oppenheimer Healthcare Conference
Dec 2, 2014
Insulet Corp at Piper Jaffray Healthcare Conference
Nov 20, 2014
Insulet Corp at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 11, 2014
Insulet Corp at Stephens Fall Investment Conference
Nov 5, 2014
Q3 2014 Insulet Corp Earnings Call
Nov 5, 2014
Q3 2014 Insulet Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -14.46% -18.20%
Operating margin -9.52% -11.79%
EBITD margin - -7.01%
Return on average assets -13.89% -18.51%
Return on average equity -54.98% -53.30%
Employees 478 -
CDP Score - -

Address

600 Technology Park Dr Ste 200
BILLERICA, MA 01821-4154
United States - Map
+1-978-6007000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insulet Corporation is engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (the OmniPod System). The OmniPod System is an insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the Company's handheld, wireless Personal Diabetes Manager (PDM). The OmniPod Insulin Management System is designed to provide people with insulin-dependent diabetes with a diabetes management solution which provides lifestyle and other benefits and to expand the use of continuous subcutaneous insulin infusion (CSII) therapy. The OmniPod operates up to 72 hours (but no more than 80 hours) after it is activated.

Officers and directors

Allison Dorval Chief Financial Officer
Age: 39
Bio & Compensation  - Reuters
William Patrick Ryan Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Bradley Thomas CFA Executive Vice President - Human Resources & Organizational Development
Bio & Compensation  - Reuters
R. Anthony Anthony Diehl Esq. General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Patrick J. Sullivan President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Sally W Crawford Lead Independent Director
Age: 60
Bio & Compensation  - Reuters
Charles T Liamos Director
Age: 54
Bio & Compensation  - Reuters
Timothy J. Scannell Director
Age: 49
Bio & Compensation  - Reuters
John A. Fallon M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Daniel J. Levangie Independent Director
Age: 63
Bio & Compensation  - Reuters